$CFRX

ContraFect Corp

  • NASDAQ
  • Health Technology
  • Biotechnology
  • Manufacturing
  • Pharmaceutical Preparation Manufacturing

PRICE

$3.29 ▲5.112%

Delayed Price

VOLUME

26,490

DAY RANGE

-

52 WEEK

2.11 - 4.76

Join Discuss about CFRX with like-minded investors

profile
@HeyShoe #droscrew
recently

RECAP 10/13 Chatter: $DKNG + NHL $M - No E-Commerce spin $BA - FAA Consider Engine redesign $CTXS + $AVGO (Gordon Haskett) $EA - FIFA Talks stall $TWTR + Conversation Ads $ZNGA+ $DIS Game collab? $UPS - $AMZN Cargo jet shopping $ORPH + Patent $CFRX + Patent $LULU + Footwear

75 Replies 11 👍 13 🔥

Key Metrics

Market Cap

123.11 M

Beta

1.33

Avg. Volume

113.01 K

Shares Outstanding

39.33 M

Yield

0%

Public Float

0

Next Earnings Date

2022-08-12

Next Dividend Date

Company Information

ContraFect is a biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. An estimated 700,000 deaths worldwide each year are attributed to antimicrobial-resistant infections. The Company intends to address life threatening infections using its therapeutic product candidates from its platform of DLAs, which include lysins and amurin peptides. Lysins are a new class of DLAs which are recombinantly produced antimicrobial proteins with a novel mechanism of action associated with the rapid killing of target bacteria, eradication of biofilms and synergy with conventional antibiotics. Amurin peptides are a novel class of DLAs which exhibit broad-spectrum activity against a wide range of antibiotic-resistant Gram-negative pathogens, including P. aeruginosa, Acinetobacter baumannii, and Enterobacter species. The Comapny believes that the properties of its lysins and amurin peptides will make them suitable for targeting antibiotic-resistant organisms, such as MRSA and P. aeruginosa, which can cause serious infections such as bacteremia, pneumonia and osteomyelitis. It has completed a Phase 2 clinical trial for the treatment of Staph aureus bacteremia, including endocarditis, with its lead lysin candidate, exebacase, which is the first lysin to enter clinical studies in the U.S. Exebacase, currently being studied in a pivotal Phase 3 clinical study, was granted Breakthrough Therapy designation by the FDA for the treatment of MRSA bloodstream infections, including right-sided endocarditis, when used in addition to SOC anti-staphylococcal antibiotics in adult patients.

CEO: Roger Pomerantz

Website:

HQ: 28 Wells Ave Ste 3 Yonkers, 10701-7045 New York

Related News